Steven Leonard Chapman Sells 3,648 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 3,648 shares of the company’s stock in a transaction on Wednesday, January 28th. The shares were sold at an average price of $237.66, for a total transaction of $866,983.68. Following the completion of the sale, the chief executive officer directly owned 213,180 shares in the company, valued at approximately $50,664,358.80. This represents a 1.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, January 27th, Steven Leonard Chapman sold 2,322 shares of Natera stock. The stock was sold at an average price of $240.53, for a total transaction of $558,510.66.
• On Wednesday, January 21st, Steven Leonard Chapman sold 1,590 shares of Natera stock. The shares were sold at an average price of $235.00, for a total transaction of $373,650.00.
• On Tuesday, January 20th, Steven Leonard Chapman sold 71,932 shares of Natera stock. The stock was sold at an average price of $234.74, for a total value of $16,885,317.68.
• On Friday, January 2nd, Steven Leonard Chapman sold 3,848 shares of Natera stock. The stock was sold at an average price of $229.08, for a total value of $881,499.84.
• On Monday, December 1st, Steven Leonard Chapman sold 4,400 shares of Natera stock. The shares were sold at an average price of $238.07, for a total value of $1,047,508.00.
• On Monday, November 3rd, Steven Leonard Chapman sold 160,703 shares of Natera stock. The stock was sold at an average price of $199.96, for a total value of $32,134,171.88.

Natera Stock Performance

Shares of NTRA stock opened at $231.14 on Friday. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $256.36. The stock has a 50 day simple moving average of $235.91 and a two-hundred day simple moving average of $193.80. The company has a market cap of $31.97 billion, a P/E ratio of -100.93 and a beta of 1.62.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The company had revenue of $592.18 million for the quarter, compared to analyst estimates of $514.55 million. During the same period last year, the business earned ($0.26) EPS. The business’s quarterly revenue was up 34.7% compared to the same quarter last year. On average, research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on NTRA. Zacks Research upgraded Natera from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. Citigroup began coverage on Natera in a report on Wednesday, January 7th. They issued a “buy” rating and a $300.00 price target on the stock. Wells Fargo & Company boosted their price objective on Natera from $190.00 to $205.00 and gave the company an “equal weight” rating in a report on Monday, December 15th. Evercore ISI upped their target price on Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Finally, Stephens increased their target price on Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $249.20.

Key Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced completion of enrollment in the randomized ACES‑EMB heart‑transplant trial — a clinical milestone for the transplant franchise (Prospera) that de‑risks the program’s pathway to clinical readouts and potential uptake. Article Title
• Positive Sentiment: Wall Street coverage remains largely favorable: multiple firms maintain buy/outperform views and several have raised targets (MarketBeat summary shows consensus around a “Moderate Buy” and an average target near $249). This supports upside expectations if results and growth continue.
• Neutral Sentiment: Natera reported preliminary Q4 revenue (details in the alert). Preliminary figures may influence sentiment when the final quarter report and guidance are released; investors should watch the formal Q4 release for confirmation versus consensus. Preliminary Q4 Revenue
• Neutral Sentiment: Institutional ownership remains extremely high (~99.9%), which tends to stabilize the shareholder base but can also concentrate selling/Buying flows when large holders move. (Source: MarketBeat summary.) Institutional Data
• Negative Sentiment: Multiple insider sales by senior executives: CFO Michael Burkes Brophy sold several tranches (totaling 5,064 shares across Jan. 20–29) and CEO Steven Chapman sold several thousand shares (roughly 5,970 shares across Jan. 27–28). These trades total millions of dollars and may create short‑term selling pressure despite insiders retaining large residual stakes. CFO Form 4 CEO Form 4
• Negative Sentiment: Other insiders (John Fesko, Solomon Moshkevich) also sold smaller tranches. While each reduction is under ~1% of those insiders’ holdings, the cluster of sales amplifies negative signaling to the market. Fesko Form 4 Moshkevich Form 4

Hedge Funds Weigh In On Natera

A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Natera by 2.3% in the second quarter. Vanguard Group Inc. now owns 12,676,653 shares of the medical research company’s stock valued at $2,141,594,000 after purchasing an additional 282,826 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Natera by 9.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock valued at $1,871,914,000 after buying an additional 1,003,129 shares during the last quarter. State Street Corp lifted its position in shares of Natera by 2.2% during the 3rd quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock worth $545,624,000 after buying an additional 72,087 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of Natera by 37.5% in the 3rd quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock worth $428,987,000 after buying an additional 727,366 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Natera by 7.0% in the 2nd quarter. Geode Capital Management LLC now owns 2,552,725 shares of the medical research company’s stock worth $430,640,000 after buying an additional 166,768 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.